Cantor Fitzgerald Weighs in on BioCryst Pharmaceuticals, Inc.’s FY2022 Earnings (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXGet Rating) – Research analysts at Cantor Fitzgerald issued their FY2022 earnings estimates for BioCryst Pharmaceuticals in a research note issued on Monday, May 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the biotechnology company will earn ($1.30) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Rating) last issued its earnings results on Wednesday, February 23rd. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.09). The firm had revenue of $47.16 million during the quarter, compared to the consensus estimate of $48.18 million.

A number of other research firms have also issued reports on BCRX. StockNews.com started coverage on BioCryst Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Zacks Investment Research lowered BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. Piper Sandler lowered their price objective on BioCryst Pharmaceuticals from $24.00 to $19.00 in a research note on Thursday, May 5th. Oppenheimer lowered their price objective on BioCryst Pharmaceuticals from $20.00 to $16.00 and set an “outperform” rating for the company in a research note on Monday, April 11th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 24th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $17.92.

BCRX stock opened at $7.94 on Thursday. BioCryst Pharmaceuticals has a 1 year low of $7.75 and a 1 year high of $19.99. The firm has a market cap of $1.47 billion, a P/E ratio of -7.42 and a beta of 2.51. The stock has a 50-day simple moving average of $13.39 and a 200-day simple moving average of $13.97.

In other news, insider Helen M. Thackray sold 7,600 shares of the company’s stock in a transaction that occurred on Friday, April 1st. The stock was sold at an average price of $16.20, for a total value of $123,120.00. Following the sale, the insider now directly owns 136,400 shares in the company, valued at approximately $2,209,680. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director George B. Abercrombie sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 15th. The stock was sold at an average price of $18.50, for a total value of $92,500.00. The disclosure for this sale can be found here. Corporate insiders own 4.80% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Semmax Financial Advisors Inc. raised its position in shares of BioCryst Pharmaceuticals by 389.6% during the 1st quarter. Semmax Financial Advisors Inc. now owns 1,699 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,352 shares during the last quarter. Point72 Hong Kong Ltd bought a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at $28,000. Strs Ohio bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter valued at $32,000. Russell Investments Group Ltd. bought a new stake in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at $29,000. Finally, Fairfield Bush & CO. bought a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter valued at $34,000. Institutional investors own 63.86% of the company’s stock.

About BioCryst Pharmaceuticals (Get Rating)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Featured Stories

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.